Copper-62-pyruvaldehyde bis(N4-methyl-thiosemicarbazone) PET imaging in the detection of coronary artery disease in humans

T. R. Wallhaus, J. Lacy, R. Stewart, J. Bianco, Mark Green, N. Nayak, C. K. Stone

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background. Copper-62 (II)-pyruvaldehyde bis(N4-methyl-thiosemicarbazone) (PTSM) has been proposed for cardiac imaging with positron emission tomography (PET). This study evaluated the agreement between Cu-62-PTSM and coronary angiography in the detection of occlusive coronary artery disease. The normalcy rate for Cu-62-PTSM PET in a group of healthy volunteers was also assessed. Methods and Results. Forty-five subjects completed the study. Twenty-eight patients underwent stress technetium-99m sestamibi single photon emission computed tomography (SPECT) imaging and cardiac catheterization followed by Cu-62-PTSM rest/dipyridamole stress PET scans, and 17 volunteers underwent Cu-62-PTSM rest/dipyridamole stress PET scans. Cu-62- PTSM myocardial perfusion defects were identified in 100% of patients with 3-vessel disease (n=8), 100% of patients with 2-vessel disease (n=9), and 67% of patients with single-vessel disease (n=6). When considering individual vessels, Cu-62-PTSM perfusion defects were seen in 72% of patients with occlusive disease in the left anterior descending artery territory, 67% in the left circumflex artery territory, and 60% in the right coronary artery territory, respectively. All 17 healthy volunteers had Cu-62-PTSM scans interpreted as normal, for a normalcy rate of 100%. Conclusions. Perfusion abnormalities are demonstrated by means of Cu-62-PTSM PET in 91% of patients with occlusive coronary artery disease seen at the time of cardiac catheterization, and it shows an excellent normalcy rate of 100%.

Original languageEnglish (US)
Pages (from-to)67-74
Number of pages8
JournalJournal of Nuclear Cardiology
Volume8
Issue number1
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Thiosemicarbazones
Pyruvaldehyde
Positron-Emission Tomography
Copper
Coronary Artery Disease
Dipyridamole
Perfusion
Cardiac Catheterization
Healthy Volunteers
Arteries
Technetium Tc 99m Sestamibi
copper pyruvaldehyde bis(N(4)-methylthiosemicarbazone) complex
Single-Photon Emission-Computed Tomography
Coronary Angiography
Volunteers
Coronary Vessels

Keywords

  • Copper-62 (II)-pyruvaldehyde bis(N-methyl-thiosemicarbazone)
  • Coronary artery disease
  • Positron emission tomography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Copper-62-pyruvaldehyde bis(N4-methyl-thiosemicarbazone) PET imaging in the detection of coronary artery disease in humans. / Wallhaus, T. R.; Lacy, J.; Stewart, R.; Bianco, J.; Green, Mark; Nayak, N.; Stone, C. K.

In: Journal of Nuclear Cardiology, Vol. 8, No. 1, 2001, p. 67-74.

Research output: Contribution to journalArticle

Wallhaus, T. R. ; Lacy, J. ; Stewart, R. ; Bianco, J. ; Green, Mark ; Nayak, N. ; Stone, C. K. / Copper-62-pyruvaldehyde bis(N4-methyl-thiosemicarbazone) PET imaging in the detection of coronary artery disease in humans. In: Journal of Nuclear Cardiology. 2001 ; Vol. 8, No. 1. pp. 67-74.
@article{0189f5fd5c504b2ba18068e6876d8149,
title = "Copper-62-pyruvaldehyde bis(N4-methyl-thiosemicarbazone) PET imaging in the detection of coronary artery disease in humans",
abstract = "Background. Copper-62 (II)-pyruvaldehyde bis(N4-methyl-thiosemicarbazone) (PTSM) has been proposed for cardiac imaging with positron emission tomography (PET). This study evaluated the agreement between Cu-62-PTSM and coronary angiography in the detection of occlusive coronary artery disease. The normalcy rate for Cu-62-PTSM PET in a group of healthy volunteers was also assessed. Methods and Results. Forty-five subjects completed the study. Twenty-eight patients underwent stress technetium-99m sestamibi single photon emission computed tomography (SPECT) imaging and cardiac catheterization followed by Cu-62-PTSM rest/dipyridamole stress PET scans, and 17 volunteers underwent Cu-62-PTSM rest/dipyridamole stress PET scans. Cu-62- PTSM myocardial perfusion defects were identified in 100{\%} of patients with 3-vessel disease (n=8), 100{\%} of patients with 2-vessel disease (n=9), and 67{\%} of patients with single-vessel disease (n=6). When considering individual vessels, Cu-62-PTSM perfusion defects were seen in 72{\%} of patients with occlusive disease in the left anterior descending artery territory, 67{\%} in the left circumflex artery territory, and 60{\%} in the right coronary artery territory, respectively. All 17 healthy volunteers had Cu-62-PTSM scans interpreted as normal, for a normalcy rate of 100{\%}. Conclusions. Perfusion abnormalities are demonstrated by means of Cu-62-PTSM PET in 91{\%} of patients with occlusive coronary artery disease seen at the time of cardiac catheterization, and it shows an excellent normalcy rate of 100{\%}.",
keywords = "Copper-62 (II)-pyruvaldehyde bis(N-methyl-thiosemicarbazone), Coronary artery disease, Positron emission tomography",
author = "Wallhaus, {T. R.} and J. Lacy and R. Stewart and J. Bianco and Mark Green and N. Nayak and Stone, {C. K.}",
year = "2001",
doi = "10.1067/mnc.2001.109929",
language = "English (US)",
volume = "8",
pages = "67--74",
journal = "Journal of Nuclear Cardiology",
issn = "1071-3581",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Copper-62-pyruvaldehyde bis(N4-methyl-thiosemicarbazone) PET imaging in the detection of coronary artery disease in humans

AU - Wallhaus, T. R.

AU - Lacy, J.

AU - Stewart, R.

AU - Bianco, J.

AU - Green, Mark

AU - Nayak, N.

AU - Stone, C. K.

PY - 2001

Y1 - 2001

N2 - Background. Copper-62 (II)-pyruvaldehyde bis(N4-methyl-thiosemicarbazone) (PTSM) has been proposed for cardiac imaging with positron emission tomography (PET). This study evaluated the agreement between Cu-62-PTSM and coronary angiography in the detection of occlusive coronary artery disease. The normalcy rate for Cu-62-PTSM PET in a group of healthy volunteers was also assessed. Methods and Results. Forty-five subjects completed the study. Twenty-eight patients underwent stress technetium-99m sestamibi single photon emission computed tomography (SPECT) imaging and cardiac catheterization followed by Cu-62-PTSM rest/dipyridamole stress PET scans, and 17 volunteers underwent Cu-62-PTSM rest/dipyridamole stress PET scans. Cu-62- PTSM myocardial perfusion defects were identified in 100% of patients with 3-vessel disease (n=8), 100% of patients with 2-vessel disease (n=9), and 67% of patients with single-vessel disease (n=6). When considering individual vessels, Cu-62-PTSM perfusion defects were seen in 72% of patients with occlusive disease in the left anterior descending artery territory, 67% in the left circumflex artery territory, and 60% in the right coronary artery territory, respectively. All 17 healthy volunteers had Cu-62-PTSM scans interpreted as normal, for a normalcy rate of 100%. Conclusions. Perfusion abnormalities are demonstrated by means of Cu-62-PTSM PET in 91% of patients with occlusive coronary artery disease seen at the time of cardiac catheterization, and it shows an excellent normalcy rate of 100%.

AB - Background. Copper-62 (II)-pyruvaldehyde bis(N4-methyl-thiosemicarbazone) (PTSM) has been proposed for cardiac imaging with positron emission tomography (PET). This study evaluated the agreement between Cu-62-PTSM and coronary angiography in the detection of occlusive coronary artery disease. The normalcy rate for Cu-62-PTSM PET in a group of healthy volunteers was also assessed. Methods and Results. Forty-five subjects completed the study. Twenty-eight patients underwent stress technetium-99m sestamibi single photon emission computed tomography (SPECT) imaging and cardiac catheterization followed by Cu-62-PTSM rest/dipyridamole stress PET scans, and 17 volunteers underwent Cu-62-PTSM rest/dipyridamole stress PET scans. Cu-62- PTSM myocardial perfusion defects were identified in 100% of patients with 3-vessel disease (n=8), 100% of patients with 2-vessel disease (n=9), and 67% of patients with single-vessel disease (n=6). When considering individual vessels, Cu-62-PTSM perfusion defects were seen in 72% of patients with occlusive disease in the left anterior descending artery territory, 67% in the left circumflex artery territory, and 60% in the right coronary artery territory, respectively. All 17 healthy volunteers had Cu-62-PTSM scans interpreted as normal, for a normalcy rate of 100%. Conclusions. Perfusion abnormalities are demonstrated by means of Cu-62-PTSM PET in 91% of patients with occlusive coronary artery disease seen at the time of cardiac catheterization, and it shows an excellent normalcy rate of 100%.

KW - Copper-62 (II)-pyruvaldehyde bis(N-methyl-thiosemicarbazone)

KW - Coronary artery disease

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=0035087032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035087032&partnerID=8YFLogxK

U2 - 10.1067/mnc.2001.109929

DO - 10.1067/mnc.2001.109929

M3 - Article

C2 - 11182711

AN - SCOPUS:0035087032

VL - 8

SP - 67

EP - 74

JO - Journal of Nuclear Cardiology

JF - Journal of Nuclear Cardiology

SN - 1071-3581

IS - 1

ER -